Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
| Ticker |
Sentiment |
Impact |
|
ILMN
|
Neutral
|
10 %
|
|
KRYS
|
Somewhat Bullish
|
21 %
|
|
FULC
|
Neutral
|
21 %
|
